Industry to publish all Phase III trials in peer-reviewed journals
This article was originally published in SRA
Executive Summary
The International Federation of Pharmaceutical Manufacturers and Associations and its members have committed to submitting the results of all industry-sponsored Phase III clinical trials for publication in scientific peer-reviewed journals. However, Germany’s health technology appraisal institute, IQWiG, said that the IFPMA’s bid to improve transparency does not go far enough to prevent publication bias.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.